Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/120650
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPerrin, S.L.en
dc.contributor.authorSamuel, M.S.en
dc.contributor.authorKoszyca, B.en
dc.contributor.authorBrown, M.P.en
dc.contributor.authorEbert, L.M.en
dc.contributor.authorOksdath, M.en
dc.contributor.authorGomez, G.A.en
dc.date.issued2019en
dc.identifier.citationBiochemical Society Transactions, 2019; 47(2):625-638en
dc.identifier.issn0300-5127en
dc.identifier.issn1470-8752en
dc.identifier.urihttp://hdl.handle.net/2440/120650-
dc.description.abstractGlioblastoma is the deadliest form of brain cancer. Aside from inadequate treatment options, one of the main reasons glioblastoma is so lethal is the rapid growth of tumour cells coupled with continuous cell invasion into surrounding healthy brain tissue. Significant intra- and inter-tumour heterogeneity associated with differences in the corresponding tumour microenvironments contributes greatly to glioblastoma progression. Within this tumour microenvironment, the extracellular matrix profoundly influences the way cancer cells become invasive, and changes to extracellular (pH and oxygen levels) and metabolic (glucose and lactate) components support glioblastoma growth. Furthermore, studies on clinical samples have revealed that the tumour microenvironment is highly immunosuppressive which contributes to failure in immunotherapy treatments. Although technically possible, many components of the tumour microenvironment have not yet been the focus of glioblastoma therapies, despite growing evidence of its importance to glioblastoma malignancy. Here, we review recent progress in the characterisation of the glioblastoma tumour microenvironment and the sources of tumour heterogeneity in human clinical material. We also discuss the latest advances in technologies for personalised and in vitro preclinical studies using brain organoid models to better model glioblastoma and its interactions with the surrounding healthy brain tissue, which may play an essential role in developing new and more personalised treatments for this aggressive type of cancer.en
dc.description.statementofresponsibilitySally L. Perrin, Michael S. Samuel, Barbara Koszyca, Michael P. Brown, Lisa M. Ebert, Mariana Oksdath, Guillermo A. Gomezen
dc.language.isoenen
dc.publisherPortland Pressen
dc.rights© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Socien
dc.subjectbrain organoids; clinical trials; glioblastoma; patient-derived tumour biopsies; tumour microenvironmenten
dc.titleGlioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatmentsen
dc.typeJournal articleen
dc.identifier.rmid0030111688en
dc.identifier.doi10.1042/BST20180444en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1067405en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1123816en
dc.relation.granthttp://purl.org/au-research/grants/arc/FT160100366en
dc.identifier.pubid465560-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS10en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidSamuel, M.S. [0000-0001-7880-6379]en
dc.identifier.orcidBrown, M.P. [0000-0002-5796-1932]en
dc.identifier.orcidEbert, L.M. [0000-0002-8041-9666]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.